A major structural shift in the way we produce and consume energy is underway and will accelerate significantly during the next decade. In this episode, Antipodes Portfolio Managers Alison Savas and Graham Hay discuss the decarbonisation supercycle - why it can't be ignored and how investors can gain exposure. 

In recent weeks the wheels have been turning on a market rotation as positive news continues to be released regarding the progress of COVID-19 vaccine developments. We now enter 2021 with confidence that it will be a year in which we see a continuing rebound in global economic activity with vaccine adoption acting as the accelerant. So, with this in mind, Antipodes Portfolio Managers Alison Savas and Andrew Baud discuss "reopening beneficiaries" within the beaten-down financials, retail and travel sectors.

In this special US Election episode Antipodes Chief Investment Officer, Jacob Mitchell, shares his views on the US election and the potential investment implications, both immediate and long-term. 

A COVID-19 vaccine breakthrough would have a material impact on global stock markets, so will we see a vaccine in 2021? One of the world's leading experts in vaccine development believes it's more than likely. 

Dr Michael Farzan, Professor and Chair of the Department of Immunology and Microbiology at Scripps Research Institute discusses the pathway to COVID-19 vaccination with Antipodes Healthcare Sector Head, Dr Nick Cameron.